| Title |
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|
|---|---|
| Published in |
Lancet Oncology, June 2018
|
| DOI | 10.1016/s1470-2045(18)30351-6 |
| Pubmed ID | |
| Authors |
Andrew X Zhu, Richard S Finn, Julien Edeline, Stephane Cattan, Sadahisa Ogasawara, Daniel Palmer, Chris Verslype, Vittorina Zagonel, Laetitia Fartoux, Arndt Vogel, Debashis Sarker, Gontran Verset, Stephen L Chan, Jennifer Knox, Bruno Daniele, Andrea L Webber, Scot W Ebbinghaus, Junshui Ma, Abby B Siegel, Ann-Lii Cheng, Masatoshi Kudo, KEYNOTE-224 investigators, Angela Alistar, Jamil Asselah, Jean-Frederic Blanc, Ivan Borbath, Timothy Cannon, Ki Chung, Allen Cohn, David P Cosgrove, Nevena Damjanov, Mukul Gupta, Yoshivasu Karino, Mark Karwal, Andreas Kaubisch, Robin Kelley, Jena-Luc Van Laethem, Timothy Larson, James Lee, Daneng Li, Atisha Manhas, Gulam Abbas Manji, Kazushi Numata, Benjamin Parsons, Andrew S. Paulson, Carmine Pinto, Robert Ramirez, Suresh Ratnam, Magnus Rizell, Olivier Rosmorduc, Yvonne Sada, Yutaka Sasaki, Per I Stal, Simone Strasser, Joerg Trojan, Gina Vaccaro, Hans Van Vlierberghe, Alan Weiss, Karl-Heinz Weiss, Tatsuya Yamashita |
Login to access the Attention Digest and the Sentiment Analysis related to this output.
X Demographics
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 19 | 25% |
| Spain | 8 | 10% |
| Brazil | 7 | 9% |
| United Kingdom | 5 | 6% |
| China | 2 | 3% |
| Mexico | 2 | 3% |
| Japan | 2 | 3% |
| India | 1 | 1% |
| Argentina | 1 | 1% |
| Other | 9 | 12% |
| Unknown | 21 | 27% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 42 | 55% |
| Practitioners (doctors, other healthcare professionals) | 18 | 23% |
| Scientists | 15 | 19% |
| Science communicators (journalists, bloggers, editors) | 2 | 3% |
Mendeley demographics
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 739 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 109 | 15% |
| Student > Ph. D. Student | 65 | 9% |
| Other | 63 | 9% |
| Student > Master | 57 | 8% |
| Student > Bachelor | 54 | 7% |
| Other | 117 | 16% |
| Unknown | 274 | 37% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 245 | 33% |
| Biochemistry, Genetics and Molecular Biology | 72 | 10% |
| Agricultural and Biological Sciences | 29 | 4% |
| Immunology and Microbiology | 19 | 3% |
| Pharmacology, Toxicology and Pharmaceutical Science | 18 | 2% |
| Other | 50 | 7% |
| Unknown | 306 | 41% |